Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy

Silvia Sánchez-Ramón, Fatima Dhalla, Helen Chapel, Silvia Sánchez-Ramón, Fatima Dhalla, Helen Chapel

Abstract

Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are prone to present with antibody production deficits associated with recurrent or severe bacterial infections that might benefit from human immunoglobulin (Ig) (IVIg/SCIg) replacement therapy. However, the original IVIg trial data were done before modern therapies were available, and the current indications do not take into account the shift in the immune situation of current treatment combinations and changes in the spectrum of infections. Besides, patients affected by other B cell malignancies present with similar immunodeficiency and manifestations while they are not covered by the current IVIg indications. A potential beneficial strategy could be to vaccinate patients at monoclonal B lymphocytosis and monoclonal gammopathy of undetermined significance stages (for CLL and MM, respectively) or at B-cell malignancy diagnosis, when better antibody responses are attained. We have to re-emphasize the need for assessing and monitoring specific antibody responses; these are warranted to select adequately those patients for whom early intervention with prophylactic anti-infective therapy and/or IVIg is preferred. This review provides an overview of the current scenario, with a focus on prevention of infection in patients with hematological malignancies and the role of Ig replacement therapy.

Keywords: antibody production defect; chronic lymphocytic leukemia; hematological malignancy; hypogammaglobulinemia; multiple myeloma; replacement immunoglobulins.

References

    1. Pisciotta AV, Jermain LF, Hinz JE. Chronic lymphocytic leukemia, hypogammaglobulinemia and autoimmune hemolytic anemia – an experiment of nature. Blood (1960) 15:748–57.
    1. Rundles RW, Moore JO. Chronic lymphocytic leukemia. Cancer (1978) 42(2 Suppl):941–5.
    1. Bussel JB, Cunningham-Rundles C. Intravenous usage of gammaglobulin: humoral immunodeficiency, immune thrombocytopenic purpura, and newer indications. Cancer Invest (1985) 3(4):361–6.10.3109/07357908509039797
    1. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med (1988) 319(14):902–7.10.1056/NEJM198810063191403
    1. Chapel H, Dicato M, Gamm H, Brennan V, Ries F, Bunch C, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol (1994) 88(1):209–12.10.1111/j.1365-2141.1994.tb05002.x
    1. Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol (1995) 17(1):75–80.10.1111/j.1365-2257.1995.tb00322.x
    1. Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull (2008) 87:49–62.10.1093/bmb/ldn034
    1. Morrison VA. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma (2009) 9(5):365–70.10.3816/CLM.2009.n.071
    1. Dhalla F, Lucas M, Schuh A, Bhole M, Jain R, Patel SY, et al. Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin? J Clin Immunol (2014) 34(3):277–82.10.1007/s10875-014-9995-5
    1. Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica (2015) 100(1):107–13.10.3324/haematol.2014.107714
    1. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis (2009) 49(8):1211–25.10.1086/605664
    1. O’Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program (2003) 1:438–72.10.1182/asheducation-2003.1.438
    1. Griffiths H, Lea J, Bunch C, Lee M, Chapel H. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol (1992) 89(3):374–7.10.1111/j.1365-2249.1992.tb06965.x
    1. Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer (2015) 121(17):2883–91.10.1002/cncr.29518
    1. Chiorazzi N, Fu SM, Montazeri G, Kunkel HG, Rai K, Gee T. T cell helper defect in patients with chronic lymphocytic leukemia. J Immunol (1979) 122(3):1087–90.
    1. Chapel HM, Bunch C. Mechanisms of infection in chronic lymphocytic leukemia. Semin Hematol (1987) 24(4):291–6.
    1. Aittoniemi J, Miettinen A, Laine S, Sinisalo M, Laippala P, Vilpo L, et al. Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia. Leuk Lymphoma (1999) 34(3–4):381–5.10.3109/10428199909050963
    1. Foa R, Fierro MT, Lusso P, Raspadori D, Ferrando ML, Matera L, et al. Reduced natural killer T-cells in B-cell chronic lymphocytic leukaemia identified by three monoclonal antibodies: Leu-11, A10, AB8.28. Br J Haematol (1986) 62(1):151–4.10.1111/j.1365-2141.1986.tb02911.x
    1. Itala M, Vainio O, Remes K. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol (1996) 57(1):46–53.10.1111/j.1600-0609.1996.tb00489.x
    1. Jurado-Camino T, Cordoba R, Esteban-Burgos L, Hernandez-Jimenez E, Toledano V, Hernandez-Rivas JA, et al. Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance. J Immunol (2015) 194(2):719–27.10.4049/jimmunol.1402272
    1. Hensel M, Kornacker M, Yammeni S, Egerer G, Ho AD. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol (2003) 122(4):600–6.10.1046/j.1365-2141.2003.04497.x
    1. Ravandi F, O’Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother (2006) 55(2):197–209.10.1007/s00262-005-0015-8
    1. Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev (2007) 21(2 Suppl 1):S9–56.10.1016/j.tmrv.2007.01.001
    1. Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med (1997) 3(9):984–9.10.1038/nm0997-984
    1. Cerutti A, Kim EC, Shah S, Schattner EJ, Zan H, Schaffer A, et al. Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells. Nat Immunol (2001) 2(2):150–6.10.1038/84254
    1. Hersey P, Wotherspoon J, Reid G, Gunz FW. Hypogammaglobulinaemia associated with abnormalities of both B and T lymphocytes in patients with chronic lymphatic leukaemia. Clin Exp Immunol (1980) 39(3):698–707.
    1. Kay NE. Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood (1981) 57(3):418–20.
    1. Sampalo A, Brieva JA. Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/CD95L in tumoral damage and escape. Leuk Lymphoma (2002) 43(4):881–4.10.1080/10428190290017033
    1. Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood (1989) 73(2):366–8.
    1. Sklenar I, Schiffman G, Jonsson V, Verhoef G, Birgens H, Boogaerts M, et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Oncology (1993) 50(6):466–77.10.1159/000227231
    1. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet (1994) 343(8905):1059–63.10.1016/S0140-6736(94)90180-5
    1. Jurlander J, Geisler CH, Hansen MM. Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol (1994) 53(2):114–8.10.1111/j.1600-0609.1994.tb01874.x
    1. Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIg) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica (1996) 81(2):121–6.
    1. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma (2009) 50(5):764–72.10.1080/10428190902856824
    1. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med (1991) 325(2):81–6.10.1056/NEJM199107113250202
    1. Gamm H, Huber C, Chapel H, Lee M, Ries F, Dicato MA. Intravenous immune globulin in chronic lymphocytic leukaemia. Clin Exp Immunol (1994) 97(Suppl 1):17–20.
    1. EMEA. Report of EMEA Expert Meeting on the Revision of the Core SPC and Note for Guidance for Human Normal Immunoglobulin for Intravenous Administration (IVIg). London: European Medicines Agency; (2008). p. 1–40. EMEA/CHMP/BPWP/361857/2006. Available from:
    1. Itala M, Helenius H, Nikoskelainen J, Remes K. Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur J Haematol (1992) 48(5):266–70.10.1111/j.1600-0609.1992.tb01805.x
    1. Young JA. Epidemiology and management of infectious complications of contemporary management of chronic leukemias. Infect Disord Drug Targets (2011) 11(1):3–10.10.2174/187152611794407755
    1. Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol (2006) 17(9):1424–7.10.1093/annonc/mdl141
    1. Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br J Haematol (2007) 137(4):349–54.10.1111/j.1365-2141.2007.06584.x
    1. Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J, et al. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest (2008) 26(4):431–3.10.1080/07357900701809068
    1. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk (2013) 13(2):106–11.10.1016/j.clml.2012.11.011
    1. Karlsson J, Andreasson B, Kondori N, Erman E, Riesbeck K, Hogevik H, et al. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom’s macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol (2011) 18(6):969–77.10.1128/CVI.00021-11
    1. Vanura K, Rieder F, Kastner MT, Biebl J, Sandhofer M, Le T, et al. Chronic lymphocytic leukemia patients have a preserved cytomegalovirus-specific antibody response despite progressive hypogammaglobulinemia. PLoS One (2013) 8(10):e78925.10.1371/journal.pone.0078925
    1. Sinisalo M, Aittoniemi J, Oivanen P, Kayhty H, Olander RM, Vilpo J. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol (2001) 114(1):107–10.10.1046/j.1365-2141.2001.02882.x
    1. Sinisalo M, Aittoniemi J, Kayhty H, Vilpo J. Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma (2003) 44(4):649–52.10.1080/1042819031000063408
    1. Pollyea DA, Brown JM, Horning SJ. Utility of influenza vaccination for oncology patients. J Clin Oncol (2010) 28(14):2481–90.10.1200/JCO.2009.26.6908
    1. Orange JS, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol (2012) 130(3 Suppl):S1–24.10.1016/j.jaci.2012.07.002
    1. Ferry BL, Misbah SA, Stephens P, Sherrell Z, Lythgoe H, Bateman E, et al. Development of an anti-Salmonella typhi Vi ELISA: assessment of immunocompetence in healthy donors. Clin Exp Immunol (2004) 136(2):297–303.10.1111/j.1365-2249.2004.02439.x
    1. Oscier D, Dearden C, Eren E, Fegan C, Follows G, Hillmen P, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol (2012) 159(5):541–64.10.1111/bjh.12067
    1. Freeman JA, Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, Han P, et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma (2013) 54(1):99–104.10.3109/10428194.2012.706285
    1. Svensson T, Hoglund M, Cherif H. Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia. Scand J Infect Dis (2013) 45(7):537–42.10.3109/00365548.2013.809623
    1. Duraisingham SS, Buckland M, Dempster J, Lorenzo L, Grigoriadou S, Longhurst HJ. Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. PLoS One (2014) 9(6):e100324.10.1371/journal.pone.0100324
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (2008) Lyon: IARC Press.
    1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood (2011) 117(19):5019–32.10.1182/blood-2011-01-293050
    1. Santos FP, O’Brien S. Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease? Cancer J (2012) 18(5):396–403.10.1097/PPO.0b013e31826cda2d
    1. Rawstron AC, Bennett FL, O’Connor SJ, Kwok M, Fenton JA, Plummer M, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med (2008) 359(6):575–83.10.1056/NEJMoa075290
    1. Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med (2009) 360(7):659–67.10.1056/NEJMoa0806122
    1. Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol (2007) 139(5):809–19.10.1111/j.1365-2141.2007.06856.x
    1. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet (2010) 376(9747):1164–74.10.1016/S0140-6736(10)61381-5
    1. Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database Syst Rev (2012) 11:CD008079.10.1002/14651858.CD008079.pub2
    1. Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, et al. Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database Syst Rev (2012) 2:CD008078.10.1002/14651858.CD008078.pub2
    1. Cramer P, Langerbeins P, Eichhorst B, Hallek M. Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). Eur J Haematol (2016) 96(1):9–18.10.1111/ejh.12678
    1. Rai KR. Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol (2015) 8:85.10.1097/00043426-198608010-00019
    1. Besada E, Bader L, Nossent H. Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: a report of two cases. Rheumatol Int (2013) 33(6):1643–4.10.1007/s00296-012-2483-4
    1. Visco C, Finotto S, Pomponi F, Sartori R, Laveder F, Trentin L, et al. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia. Am J Hematol (2013) 88(4):289–93.10.1002/ajh.23396
    1. De Angelis F, Tosti ME, Capria S, Russo E, D’Elia GM, Annechini G, et al. Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study. Leuk Res (2015) 39(12):1382–8.10.1016/j.leukres.2015.10.013
    1. Greil R, Obrtlikova P, Smolej L, Kozak T, Steurer M, Andel J, et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol (2016) 3(7):e317–29.10.1016/S2352-3026(16)30045-X
    1. Tuccori M, Focosi D, Blandizzi C, Pelosini M, Montagnani S, Maggi F, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin’s lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist (2010) 15(11):1214–9.10.1634/theoncologist.2010-0098
    1. Ozoya OO, Sokol L, Dalia S. Hepatitis B reactivation with novel agents in non-Hodgkin’s lymphoma and prevention strategies. J Clin Transl Hepatol (2016) 4(2):143–50.10.14218/JCTH.2016.00005
    1. Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 23(18):4079–88.10.1200/JCO.2005.12.051
    1. Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol (2006) 33(2):240–9.10.1053/j.seminoncol.2005.12.013
    1. Jiang X, Mei X, Feng D, Wang X. Prophylaxis and treatment of Pneumocystis jirovecii pneumonia in lymphoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis. PLoS One (2015) 10(4):e0122171.10.1371/journal.pone.0116010
    1. Polito L, Bortolotti M, Maiello S, Battelli MG, Bolognesi A. Rituximab and other new anti-CD20 MABs for non-Hodgkin’s lymphoma treatment. EMJ Oncol (2014) 2:63–9.
    1. Shah A. New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab. Ther Clin Risk Manag (2015) 11:1113–22.10.2147/TCRM.S71839
    1. Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SE, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood (2015) 126(19):2213–9.10.1182/blood-2015-04-639203
    1. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med (2016) 374(4):323–32.10.1056/NEJMoa1509981
    1. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med (2015) 373(25):2425–37.10.1056/NEJMoa1509388
    1. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med (2014) 370(11):997–1007.10.1056/NEJMoa1315226
    1. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med (2014) 370(11):1008–18.10.1056/NEJMoa1314583
    1. O’Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, et al. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood (2015) 126(25):2686–94.10.1182/blood-2015-03-630947
    1. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol (2016) 17(6):768–78.10.1016/S1470-2045(16)30019-5
    1. Durandy A, Kracker S, Fischer A. Primary antibody deficiencies. Nat Rev Immunol (2013) 13(7):519–33.10.1038/nri3466
    1. Perez de Diego R, Sanchez-Ramon S, Lopez-Collazo E, Martinez-Barricarte R, Cubillos-Zapata C, Ferreira Cerdan A, et al. Genetic errors of the human caspase recruitment domain-B-cell lymphoma 10-mucosa-associated lymphoid tissue lymphoma-translocation gene 1 (CBM) complex: molecular, immunologic, and clinical heterogeneity. J Allergy Clin Immunol (2015) 136(5):1139–49.10.1016/j.jaci.2015.06.031
    1. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med (2015) 7(303):303ra139.10.1126/scitranslmed.aac5415
    1. Singh N, Frey NV, Grupp SA, Maude SL. CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia. Curr Treat Options Oncol (2016) 17(6):28.10.1007/s11864-016-0406-4
    1. Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy. Blood (2016) 128(3):360–70.10.1182/blood-2016-01-694356
    1. Foran JM. Antibody-based therapy of non-Hodgkin’s lymphoma. Best Pract Res Clin Haematol (2002) 15(3):449–65.10.1053/beha.2002.0222
    1. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood (2011) 117(10):2807–12.10.1182/blood-2011-03-340307
    1. Hua Q, Zhu Y, Liu H. Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin’s lymphoma (B-NHL) chemotherapy: a meta-analysis. J Chemother (2015) 27(6):365–70.10.1179/1973947815Y.0000000025
    1. Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, et al. [Immunoglobulin substitution in patients with indolent non-Hodgkin’s lymphoma]. Dtsch Med Wochenschr (2015) 140(19):e201–6.10.1055/s-0041-102631
    1. Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, et al. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol (2011) 128(6):1295–1302e1295.10.1016/j.jaci.2011.08.008
    1. Cambridge G, Perry HC, Nogueira L, Serre G, Parsons HM, De La Torre I, et al. The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. J Autoimmun (2014) 50:67–76.10.1016/j.jaut.2013.12.002
    1. Irie E, Shirota Y, Suzuki C, Tajima Y, Ishizawa K, Kameoka J, et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol (2010) 91(3):501–8.10.1007/s12185-010-0528-6
    1. Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun (2015) 57:60–5.10.1016/j.jaut.2014.11.004
    1. Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma (2006) 47(6):1013–7.10.1080/10428190500473113
    1. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol (2010) 47(2):187–98.10.1053/j.seminhematol.2010.01.002
    1. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum (2010) 62(9):2625–32.10.1002/art.27555
    1. De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (Oxford) (2012) 51(5):833–40.10.1093/rheumatology/ker417
    1. Kotton CN, Poznanski MC. Vaccination of oncology patients: an effective tool and an opportunity not to be missed. Oncologist (2012) 17(1):1–2.10.1634/theoncologist.2011-0383
    1. Tsigrelis C, Ljungman P. Vaccinations in patients with hematological malignancies. Blood Rev (2016) 30(2):139–47.10.1016/j.blre.2015.10.001
    1. Pasiarski M, Rolinski J, Grywalska E, Stelmach-Goldys A, Korona-Glowniak I, Gozdz S, et al. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients – preliminary report. PLoS One (2014) 9(12):e114966.10.1371/journal.pone.0114966
    1. van der Velden AM, Mulder AH, Hartkamp A, Diepersloot RJ, van Velzen-Blad H, Biesma DH. Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients. Eur J Intern Med (2001) 12(5):420–4.10.1016/S0953-6205(01)00149-2
    1. de Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica (2011) 96(2):307–14.10.3324/haematol.2010.032664
    1. Vinograd I, Baslo R, Eliakim-Raz N, Farbman L, Taha A, Sakhnini A, et al. Factors associated with influenza vaccination among adult cancer patients: a case-control study. Clin Microbiol Infect (2014) 20(9):899–905.10.1111/1469-0691.12625
    1. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2015) 26(Suppl 5):v78–84.10.1093/annonc/mdv233.265
    1. Sinisalo M, Vilpo J, Itala M, Vakevainen M, Taurio J, Aittoniemi J. Efficacy of pneumococcal vaccination on chronic lymphocytic leukemia: should we rely on surrogate markers? Vaccine (2008) 26(32):3959.10.1016/j.vaccine.2008.04.063
    1. Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ, Group S. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect (2010) 138(12):1804–10.10.1017/S0950268809991555
    1. Sinsalo M, Aittoniemi J, Kayhty H, Vilpo J. Haemophilus influenzae type b (Hib) antibody concentrations and vaccination responses in patients with chronic lymphocytic leukaemia: predicting factors for response. Leuk Lymphoma (2002) 43(10):1967–9.10.1080/1042819021000015916
    1. Brenol CV, da Mota LM, Cruz BA, Pileggi GS, Pereira IA, Rezende LS, et al. 2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis. Rev Bras Reumatol (2013) 53(1):4–23.10.1016/S2255-5021(13)70002-6
    1. Santoro A, Rilke F, Franchi F, Monfardini S. Primary malignant neoplasms associated with chronic lymphocytic leukemia. Tumori (1980) 66(4):431–7.
    1. Brewer JD, Shanafelt TD, Khezri F, Sosa Seda IM, Zubair AS, Baum CL, et al. Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester epidemiology project population-based study in Minnesota. J Am Acad Dermatol (2015) 72(2):302–9.10.1016/j.jaad.2014.10.028
    1. Flynn JM, Andritsos L, Lucas D, Byrd JC. Second malignancies in B-cell chronic lymphocytic leukaemia: possible association with human papilloma virus. Br J Haematol (2010) 149(3):388–90.10.1111/j.1365-2141.2010.08110.x
    1. Whitaker JA, Shanafelt TD, Poland GA, Kay NE. Room for improvement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia. Clin Adv Hematol Oncol (2014) 12(7):440–50.10.1038/leu.2012.187
    1. Obeid KM, Aguilar J, Szpunar S, Sharma M, del Busto R, Al-Katib A, et al. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders. Clin Lymphoma Myeloma Leuk (2012) 12(1):66–9.10.1016/j.clml.2011.07.006
    1. Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol (2009) 88(2):121–32.10.1007/s00277-008-0566-9
    1. O’Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma (2006) 7(2):125–30.
    1. Osterborg A, Foà R, Bezares RF, Dearden C, Dyer MJ, Geisler C, et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia (2009) 23(11):1980–8.10.1038/leu.2009.146
    1. Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol (2010) 28(19):3199–202.10.1200/JCO.2010.30.0673
    1. Lyman GH. Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone (2006) 8(Suppl 5):S12–8.10.1016/S1098-3597(06)80054-2
    1. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 24(19):3187–205.10.1200/JCO.2006.06.4451
    1. Dale DC. Advances in the treatment of neutropenia. Curr Opin Support Palliat Care (2009) 3(3):207–12.10.1097/SPC.0b013e32832ea6ae
    1. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol (2010) 125(6):1354–1360e1354.10.1016/j.jaci.2010.02.040
    1. Provan D, Chapel HM, Sewell WA, O’Shaughnessy D, UK Immunoglobulin Expert Working Group Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. BMJ (2008) 337:a1831.10.1136/bmj.a1831
    1. Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol (2006) 26(1):65–72.10.1007/s10875-006-8905-x
    1. Blombery P, Prince HM, Worth LJ, Main J, Yang M, Wood EM, et al. Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. Ann Hematol (2011) 90(10):1167–72.10.1007/s00277-011-1275-3
    1. Ichihara H, Nakamae H, Hirose A, Nakane T, Koh H, Hayashi Y, et al. Immunoglobulin prophylaxis against cytomegalovirus infection in patients at high risk of infection following allogeneic hematopoietic cell transplantation. Transplant Proc (2011) 43(10):3927–32.10.1016/j.transproceed.2011.08.104
    1. Khalafallah A, McDonnell K, Dawar HU, Robertson I, Woods D. Quality of life assessment in multiple myeloma patients undergoing dose-reduced tandem autologous stem cell transplantation. Mediterr J Hematol Infect Dis (2011) 3(1):e2011057.10.4084/mjhid.2011.057
    1. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol (2011) 164(Suppl 2):2–5.10.1111/j.1365-2249.2011.04387.x
    1. Corbi AL, Sanchez-Ramon S, Dominguez-Soto A. The potential of intravenous immunoglobulins for cancer therapy: a road that is worth taking? Immunotherapy (2016) 8(5):601–12.10.2217/imt.16.9
    1. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol (1998) 161(7):3781–90.
    1. Mitrevski M, Marrapodi R, Camponeschi A, Cavaliere FM, Lazzeri C, Todi L, et al. Intravenous immunoglobulin and immunomodulation of B-cell – in vitro and in vivo effects. Front Immunol (2015) 6:4.10.3389/fimmu.2015.00004
    1. Besa EC. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am J Med (1984) 76(3A):209–18.10.1016/0002-9343(84)90344-9
    1. Paquin-Proulx D, Aubin E, Lemieux R, Bazin R. Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin Immunol (2010) 135(3):422–9.10.1016/j.clim.2010.01.001
    1. Paquin-Proulx D, Sandberg JK. Persistent immune activation in CVID and the role of IVIg in its suppression. Front Immunol (2014) 5:637.10.3389/fimmu.2014.00637
    1. Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Siberil S, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun (2011) 36(1):9–15.10.1016/j.jaut.2010.09.006
    1. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol (2009) 145(6):709–27.10.1111/j.1365-2141.2009.07669.x
    1. Cunningham-Rundles C. Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency. Clin Exp Immunol (2009) 157(Suppl 1):12–6.10.1111/j.1365-2249.2009.03952.x
    1. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. National comprehensive cancer network. Non-Hodgkin’s lymphomas, version 4.2014. J Natl Compr Canc Netw (2014) 12(9):1282–303.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj